Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly.

Tytuł:
Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly.
Autorzy:
Shen M; Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Wulumuqi Zhong Road, Shanghai, 200040, China.; Shanghai Pituitary Tumor Center, Shanghai, China.
Zhang Q; Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Wulumuqi Zhong Road, Shanghai, 200040, China.; Shanghai Pituitary Tumor Center, Shanghai, China.
Liu W; Shanghai Pituitary Tumor Center, Shanghai, China.; Department of Endocrinology and Metabolism, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Wang M; Department of Endocrinology and Metabolism, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.; Division of Endocrinology, the Second Affiliated Hospital, Soochow University, Suzhou, China.
Zhu J; Shanghai Pituitary Tumor Center, Shanghai, China.; Department of Neuropathology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Ma Z; Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Wulumuqi Zhong Road, Shanghai, 200040, China.; Shanghai Pituitary Tumor Center, Shanghai, China.
He W; Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Wulumuqi Zhong Road, Shanghai, 200040, China.; Shanghai Pituitary Tumor Center, Shanghai, China.
Li S; Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Wulumuqi Zhong Road, Shanghai, 200040, China.; Shanghai Pituitary Tumor Center, Shanghai, China.
Shou X; Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Wulumuqi Zhong Road, Shanghai, 200040, China.; Shanghai Pituitary Tumor Center, Shanghai, China.
Li Y; Shanghai Pituitary Tumor Center, Shanghai, China.; Department of Endocrinology and Metabolism, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Zhang Z; Shanghai Pituitary Tumor Center, Shanghai, China.; Department of Endocrinology and Metabolism, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Ye H; Shanghai Pituitary Tumor Center, Shanghai, China.; Department of Endocrinology and Metabolism, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
He M; Shanghai Pituitary Tumor Center, Shanghai, China.; Department of Endocrinology and Metabolism, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Lu B; Shanghai Pituitary Tumor Center, Shanghai, China.; Department of Endocrinology and Metabolism, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Yao Z; Shanghai Pituitary Tumor Center, Shanghai, China.; Department of Radiology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Lu Y; Department of Nuclear Medicine, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Qiao N; Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Wulumuqi Zhong Road, Shanghai, 200040, China.; Shanghai Pituitary Tumor Center, Shanghai, China.
Ye Z; Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Wulumuqi Zhong Road, Shanghai, 200040, China.; Shanghai Pituitary Tumor Center, Shanghai, China.
Zhang Y; Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Wulumuqi Zhong Road, Shanghai, 200040, China.; Shanghai Pituitary Tumor Center, Shanghai, China.
Yang Y; Shanghai Pituitary Tumor Center, Shanghai, China.; Department of Endocrinology and Metabolism, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Zhao Y; Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Wulumuqi Zhong Road, Shanghai, 200040, China. .; Shanghai Pituitary Tumor Center, Shanghai, China. .
Wang Y; Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Wulumuqi Zhong Road, Shanghai, 200040, China. .; Shanghai Pituitary Tumor Center, Shanghai, China. .
Źródło:
Neuroradiology [Neuroradiology] 2016 Nov; Vol. 58 (11), pp. 1057-1065. Date of Electronic Publication: 2016 Aug 11.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Berlin, New York, Springer-Verlag.
MeSH Terms:
Acromegaly/*diagnostic imaging
Acromegaly/*drug therapy
Drug Monitoring/*methods
Growth Hormone-Secreting Pituitary Adenoma/*diagnostic imaging
Growth Hormone-Secreting Pituitary Adenoma/*drug therapy
Magnetic Resonance Imaging/*methods
Somatostatin/*administration & dosage
Acromegaly/surgery ; Adult ; Female ; Growth Hormone-Secreting Pituitary Adenoma/pathology ; Humans ; Image Interpretation, Computer-Assisted/methods ; Male ; Middle Aged ; Reproducibility of Results ; Retrospective Studies ; Sensitivity and Specificity ; Treatment Outcome
References:
Endocr Pract. 2011 Jul-Aug;17 Suppl 4:1-44. (PMID: 21846616)
Eur J Endocrinol. 2014 Aug;171(2):229-35. (PMID: 24866574)
J Clin Endocrinol Metab. 1998 Aug;83(8):2646-52. (PMID: 9709926)
J Clin Endocrinol Metab. 2009 May;94(5):1509-17. (PMID: 19208732)
Eur J Endocrinol. 2006 Feb;154(2):267-74. (PMID: 16452540)
Am J Roentgenol Radium Ther Nucl Med. 1962 Jun;87:989-1008. (PMID: 13885978)
J Clin Invest. 2009 Nov;119(11):3189-202. (PMID: 19884662)
Clin Endocrinol (Oxf). 2012 Jul;77(1):72-8. (PMID: 22066905)
Eur J Radiol. 2011 Nov;80(2):412-7. (PMID: 20580505)
Endocr J. 2010;57(12):1035-44. (PMID: 21099129)
Endocr Relat Cancer. 2015 Apr;22(2):169-77. (PMID: 25556181)
J Clin Endocrinol Metab. 2010 Nov;95(11):4973-8. (PMID: 20739382)
J Clin Endocrinol Metab. 1998 Oct;83(10):3411-8. (PMID: 9768640)
J Clin Endocrinol Metab. 2013 Nov;98(11):E1730-9. (PMID: 24092823)
Radiology. 2006 Apr;239(1):223-31. (PMID: 16452397)
Endocrine. 2016 May;52(2):333-43. (PMID: 26475495)
Eur J Endocrinol. 2007 Jan;156(1):65-74. (PMID: 17218727)
J Clin Endocrinol Metab. 2013 Jan;98(1):E66-71. (PMID: 23118420)
Endocr J. 2012;59(3):221-8. (PMID: 22200580)
Acta Endocrinol (Copenh). 1989 Dec;121(6):753-8. (PMID: 2558477)
J Clin Endocrinol Metab. 2006 Apr;91(4):1397-403. (PMID: 16449332)
Endocr Rev. 2011 Apr;32(2):247-71. (PMID: 21123741)
Horm Res. 2004;62(5):227-32. (PMID: 15477693)
Growth Horm IGF Res. 2005 Jun;15(3):200-6. (PMID: 15935982)
Eur J Endocrinol. 2004 Jun;150(6):763-71. (PMID: 15191345)
J Clin Endocrinol Metab. 2005 Nov;90(11):6290-5. (PMID: 16118335)
Expert Opin Pharmacother. 2013 Dec;14(17):2433-47. (PMID: 24124691)
Front Neuroendocrinol. 1999 Jul;20(3):157-98. (PMID: 10433861)
Clin Endocrinol (Oxf). 2012 Jan;76(1):96-102. (PMID: 21722151)
Endocr J. 2004 Apr;51(2):227-36. (PMID: 15118275)
Neurology. 2016 Feb 23;86(8):731-4. (PMID: 26701376)
Eur J Endocrinol. 2013 Sep 12;169(4):391-400. (PMID: 23847328)
Trends Endocrinol Metab. 2013 May;24(5):238-46. (PMID: 23270713)
Q J Med. 1993 May;86(5):293-9. (PMID: 8327647)
Eur J Endocrinol. 2008 Mar;158(3):295-303. (PMID: 18299461)
Neuroradiology. 2016 Jan;58(1):51-7. (PMID: 26376802)
Contributed Indexing:
Keywords: Acromegaly; Magnetic resonance imaging; Relative signal intensity; Somatostatin analog; Somatostatin receptor
Substance Nomenclature:
51110-01-1 (Somatostatin)
Entry Date(s):
Date Created: 20160813 Date Completed: 20180205 Latest Revision: 20220410
Update Code:
20240104
DOI:
10.1007/s00234-016-1728-4
PMID:
27516099
Czasopismo naukowe
Introduction: The difficulty of predicting the efficacy of somatostatin analogs (SSA) is not fully resolved. Here, we quantitatively evaluated the predictive value of relative signal intensity (rSI) on T1- and T2-weighted magnetic resonance imaging (MRI) for the short-term efficacy (3 months) of SSA therapy in patients with active acromegaly and assessed the correlation between MRI rSI and expression of somatostatin receptors (SSTR).
Methods: This was a retrospective review of prospectively recorded data. Ninety-two newly diagnosed patients (37 males and 55 females) with active acromegaly were recruited. All patients were treated with pre-surgical SSA, followed by reassessment and transspenoidal surgery. rSI values were generated by calculating the ratio of SI in the tumor to the SI of normal frontal white matter. The Youden indices were calculated to determine the optimal cutoff of rSI to determine the efficacy of SSA. The correlation between rSI and expression of SSTR2/5 was analyzed by the Spearman rank correlation coefficient.
Results: T2 rSI was strongly correlated with biochemical sensitivity to SSA. The cutoff value of T2 rSI to distinguish biochemical sensitivity was 1.205, with a positive predictive value (PPV) of 81.5 % and a negative predictive value (NPV) of 77.3 %. No correlation was found between MRI and tumor size sensitivity. Moreover, T2 rSI was negatively correlated with the expression of SSTR5.
Conclusion: T2 rSI correlates with the expression of SSTR5 and quantitatively predicts the biochemical efficacy of SSA in acromegaly.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies